Aduro BioTech

Type: Company
Name: Aduro BioTech
First reported Oct 23 2014 - Updated Oct 23 2014 - 3 reports

Aduro Presents Updated Interim Results from Phase 1b Clinical Trial in Mesothelioma at International Mesothelioma Interest Group Conference

BERKELEY, Calif.--(BUSINESS WIRE)-- Aduro BioTech, Inc., a leader in cancer immunotherapy, today announced the presentation of updated safety and efficacy data from an ongoing Phase 1b clinical trial of its novel immunotherapy CRS-207 in combination with ... [Published CNBC - Oct 23 2014]
First reported Oct 21 2014 - Updated Oct 21 2014 - 1 reports

Cancer vaccine maker inks deal up to $817 million with Johnson & Johnson

Oct 16, 2014 - 18:27 GMTAduro BioTech in Berkeley has struck another big development deal with Johnson & Johnson, this time to work on its lung cancer vaccine in a partnership worth up to $817 million, the companies said Thursday.The deal is Aduro’s second ... [Published Mesothelioma News Today - Oct 21 2014]
First reported Oct 18 2014 - Updated Oct 18 2014 - 1 reports

Aduro signs a pharma deal worth $847 million with Janssen

Aduro Biotech just inked a pharma deal with the Johnson & Johnson Innovation Center in California to help it develop its nascent lung cancer therapies. Janssen Biotech, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), will receive ... [Published BioPortfolio - Oct 18 2014]
First reported Oct 16 2014 - Updated Oct 17 2014 - 10 reports

Aduro J&J in second cancer pact

Immunotherapy specialist Aduro BioTech Inc. (Berkeley, Calif.) entered into its second licensing agreement with the Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE: JNJ). The biotech granted Janssen exclusive, worldwide rights to an unsp ... [Published BioPortfolio - Oct 17 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Five things for pharma marketers to know: Thursday, October 16

Share this article: Five things for pharma marketers to know: Thursday, October 16AbbVie board recommends against Shire deal; consultancy says Netherland's generic bias hampers branded drug sales; Genentech and BI score FDA approval for fatal lung di ... [Published Medical Marketing And Media - Oct 16 2014]
First reported Oct 15 2014 - Updated Oct 15 2014 - 1 reports

Aduro BioTech Announces Interim Phase 1B Clinical Data of CRS-207 for the Treatment of Mesothelioma Accepted for Oral Presentation at the International Mesothelioma Interest Group Conference

BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a leader in cancer immunotherapy, today announced that interim data from the Phase 1B clinical trial of its CRS-207 cancer immunotherapy in combination with chemotherapy as a front line treatment ... [Published Business Wire Health News - Oct 15 2014]
First reported Oct 09 2014 - Updated Oct 09 2014 - 4 reports

Aduro Biotech???s Chief Scientific Officer, Featured Speaker On Action Of Vaccine Adjuvants At

BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a leader in the development of therapies for immuno-oncology, announced today that Thomas W. Dubensky, Jr., Ph.D., chief scientific officer at the company, was a featured speaker at the Keystone ... [Published BioSpace - Oct 09 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 2 reports

Aduro BioTech Named One of Fierce 15 Leading Biotech Companies in 2014

Today - 12:11 GMTBERKELEY, Calif., Sep 22, 2014 (BUSINESS WIRE) --Aduro BioTech, Inc., a leader in cancer immunotherapy, today announcedthat it has been named one of the leading biotech companies in 2014 byFierceBiotech, designating it as one of the industry’s ... [Published Mesothelioma News Today - Sep 22 2014]
First reported Jul 21 2014 - Updated Jul 22 2014 - 2 reports

Aduro BioTech Receives FDA Breakthrough Therapy Designation for Innovative Pancreatic Cancer Combination Immunotherapy

Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its pancreatic cancer combination treatment that consists of its CRS-207 an ... [Published BioPortfolio - Jul 21 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 5 reports

Aduro BioTech Names Industry Veteran and Academic Leader, Gerald Chan, DSc to its Board of Directors

BERKELEY, Calif.--(EON: Enhanced Online News)--Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that renowned academic leader and industry veteran, Gerald Chan, DSc has joined its board of directors. Dr. Chan is the co-founder ... [Published EON Business - Jul 17 2014]
First reported Jun 11 2014 - Updated Jun 12 2014 - 4 reports

Aduro BioTech secures $55 mln Series C

Clinical stage biotechnology company Aduro BioTech has closed a $55 million Series C financing. New investor Johnson & Johnson Development Corporation joined the Morningside group and other new and existing investors in the transaction. PRESS RELEASE ... [Published PE Hub Blog - Jun 12 2014]
First reported May 29 2014 - Updated May 30 2014 - 5 reports

Aduro licenses immunotherapy products to Janssen

Aduro BioTech Inc. (Berkeley, Calif.) granted the Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights to products based on Aduro's live-attenuated double-deleted Listeria monocytogenes (LADD) immunotherapy plat ... [Published BioPortfolio - May 30 2014]

Quotes

Original Article: NEXT ARTICLE More From BioPortfolio on "Aduro expands deal with Janssen to develop product candidates for lung cancer"
NEXT ARTICLE More From BioPortfolio on "Aduro, Janssen sign second agreement this year, this time for lung cancer"
...our technologies forward in their licensed indications," said Stephen T Isaacs, chairman president and chiefchief executive officer of Aduro. "We believe our LADD technology also offers tremendous promise as a potential treatment for lung cancer and we are pleased to expand our relationship with Janssen, a company with significant experience and resources focused in both lung and prostate cancer. Separately, Aduro continues to make progress with our broad array of immunotherapy platforms in a number of other oncology indications, including pancreatic cancer, mesothelioma and glioblastoma among others."
"The “Vaccine Market — By Technology & Types, Trend Analysis By Various Classes – Live / Attenuated, Subunit, Toxoid, Conjugate, DNA, Recombinant Vector, Synthetic, Dentritic Vaccines And By Indications – Infectious Diseases, Cancer, Allergy, Diabetes, Cardiovascular Disease With Market Landscape Analysis — Global Forecasts To 2022 ” analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia, and the Rest of the World."

More Content

All (58) | News (31) | Reports (0) | Blogs (26) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Aduro Presents Updated Interim Results from Pha... [Published CNBC - Oct 23 2014]
Aduro Presents Updated Interim Results from Pha... [Published Yahoo! Finance UK and Ireland - Oct 23 2014]
Aduro Presents Updated Interim Results from Pha... [Published Business Wire Health News - Oct 23 2014]
Cancer vaccine maker inks deal up to $817 milli... [Published Mesothelioma News Today - Oct 21 2014]
Janssen And Aduro Ink New Deal In Lung Cancer I... [Published Bioresearch Online - Oct 21 2014]
Aduro signs a pharma deal worth $847 million wi... [Published BioPortfolio - Oct 18 2014]
Aduro, Johnson & Johnson Innovation and Janssen... [Published Center Watch - Oct 18 2014]
Aduro expands deal with Janssen to develop prod... [Published BioPortfolio - Oct 17 2014]
Aduro expands deal with Janssen to develop prod... [Published PBR - News - Oct 17 2014]
Aduro expands deal with Janssen to lung cancer;... [Published Pharma Letter - Oct 17 2014]
Aduro J&J in second cancer pact [Published BioPortfolio - Oct 17 2014]
Aduro Janssen sign second agreement this year t... [Published BioPortfolio - Oct 17 2014]
J&J extends R&D pact with Aduro [Published Pharma Times - Oct 16 2014]
Five things for pharma marketers to know: Thurs... [Published Medical Marketing And Media - Oct 16 2014]
Cancer vaccine maker inks deal up to $817 milli... [Published Tech Chronicles - Oct 16 2014]
Aduro BioTech, Janssen Expand Immunotherapy Pla... [Published Contract Pharma - Oct 16 2014]
Cancer vaccine partners J&J, Aduro add $817M pact [Published FierceVaccines - Oct 16 2014]
Johnson & Johnson enters more than $800-million... [Published FirstWord Pharma - Oct 16 2014]
J&J Expands Aduro Collaboration into Prostate C... [Published Genetic Engineering News - Oct 16 2014]
Experimental lung cancer vaccine lands Berkeley... [Published San Francisco Business Times - Oct 16 2014]
Aduro Expands Collaboration with Johnson & John... [Published Scottrade - Oct 16 2014]
Aduro Expands Collaboration with Johnson & John... [Published Business Wire Health News - Oct 16 2014]
Aduro BioTech Announces Interim Phase 1B Clinic... [Published Business Wire Health News - Oct 15 2014]
Aduro Biotech???s Chief Scientific Officer, Fe... [Published BioSpace - Oct 09 2014]
Aduro BioTech’s Chief Scientific Officer, Thoma... [Published EON Science - Oct 09 2014]
Aduro BioTech’s Chief Scientific Officer, Thoma... [Published Business Wire Science: Science News - Oct 09 2014]
Aduro BioTech’s Chief Scientific Officer, Thoma... [Published Business Wire Health News - Oct 09 2014]
Global Pancreatic Cancer Market 2014-2018: Key ... [Published Individual.com - Oct 09 2014]
What will be future of Vaccine Technolology Mar... [Published Scoop Asia - Oct 01 2014]
Vaccine Technology Market worth $84.44 Billion ... [Published Scoop Asia - Sep 23 2014]
1 2
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Aduro Presents Updated Interim Results from Pha... [Published Business Wire Health News - Oct 23 2014]
BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a leader in cancer immunotherapy, today announced the presentation of updated safety and efficacy data from an ongoing Phase 1b clinical trial of its novel immunotherapy CRS-207 in combination with ...
Aduro expands deal with Janssen to develop prod... [Published PBR - News - Oct 17 2014]
Aduro BioTech has entered into its second agreement with Janssen Biotech, granting an exclusive, worldwide license to certain product candidates designed to treat lung cancer and certain other cancers based on its novel LADD immunotherapy platform. ...
Cancer vaccine maker inks deal up to $817 milli... [Published Tech Chronicles - Oct 16 2014]
Aduro BioTech in Berkeley has struck another big development deal with Johnson & Johnson, this time to work on its lung cancer vaccine in a partnership worth up to $817 million, the companies said Thursday. The deal is Aduro’s second with Janssen Biotech, ...
Aduro Expands Collaboration with Johnson & John... [Published Business Wire Health News - Oct 16 2014]
BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a leader in cancer immunotherapy, today announced that it has entered into its second agreement with Janssen Biotech, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, granting ...
Aduro BioTech Announces Interim Phase 1B Clinic... [Published Business Wire Health News - Oct 15 2014]
BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a leader in cancer immunotherapy, today announced that interim data from the Phase 1B clinical trial of its CRS-207 cancer immunotherapy in combination with chemotherapy as a front line treatment ...
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.